Standout Papers

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study 2016 2026 2019 2022 1.1k
  1. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study (2016)
    Rita Nanda, Laura Q.M. Chow et al. Journal of Clinical Oncology

Immediate Impact

6 by Nobel laureates 29 from Science/Nature 71 standout
Sub-graph 1 of 22

Citing Papers

Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
2024 Standout
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
2024 Standout

Works of Gursel Aktan being referenced

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review
2019

Author Peers

Author Last Decade Papers Cites
Gursel Aktan 2486 835 764 52 3.0k
Peter Savas 3122 959 1062 49 4.2k
Sean P. Pitroda 1693 988 652 94 3.3k
Thomas A. Puchalski 1523 822 409 50 2.8k
Gail S. Wright 2639 1078 796 19 3.5k
Marleen Kok 2167 784 851 88 3.4k
Kun He 1955 1223 463 53 3.1k
Laurence Buisseret 2535 654 567 64 3.5k
Cristina Cruz 2695 648 476 36 3.6k
Viswam S. Nair 1457 1101 773 43 3.3k
Wei Zou 2996 1959 662 56 3.5k

All Works

Loading papers...

Rankless by CCL
2026